Skip to content
Screener

Rigel Pharmaceuticals RIGL Valuation Allowances And Reserves Balance

Valuation Allowances And Reserves Balance at other companies

Service Corporation International logo
Service Corporation InternationalSCI
$108.83M-8.5%
Terex logo
TerexTEX
$117M-11.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$28.08M+0.5%
StoneX Group Inc. logo
StoneX Group Inc.SNEX
$60.8M+12.4%
StoneX Group Inc. logo
StoneX Group Inc.SNEX
$60.8M+12.4%
Exelixis logo
ExelixisEXEL
$98.92M+2.3%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ValuationAllowancesAndReservesBalance.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemChargebacks,Discounts and FeesGovernmentand Other RebatesReturnsTotal
Balance as of January 1, 2026$12,519$10,389$4,808$27,716
Provision related to current period sales14,3794,76655019,695
Adjustment related to prior period sales(363)(381)(744)
Credit or payments made during the period(14,459)(3,848)(280)(18,587)
Balance as of March 31, 2026$12,076$10,926$5,078$28,080

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's valuation allowances and reserves balance?
Rigel Pharmaceuticals (RIGL) reported valuation allowances and reserves balance of $28.08M in Q1 2026.
How has Rigel Pharmaceuticals's valuation allowances and reserves balance changed year-over-year?
Rigel Pharmaceuticals's valuation allowances and reserves balance increased by 0.5% year-over-year, from $27.94M to $28.08M.
What is the long-term trend for Rigel Pharmaceuticals's valuation allowances and reserves balance?
Over 2 years (2023 to 2025), Rigel Pharmaceuticals's valuation allowances and reserves balance has grown at a 32.9% compound annual growth rate (CAGR), from $15.68M to $27.72M.
What does valuation allowances and reserves balance mean?
This represents the cumulative balance of accounting reserves established to adjust the carrying value of assets, such as inventory obsolescence or bad debt provisions. It reflects management's assessment of potential losses or impairments in the asset base. Significant changes in these reserves can indicate shifts in asset quality or changes in the operating environment.

Ask your AI about Rigel Pharmaceuticals's valuation allowances and reserves balance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude